Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.8 NOK | -.--% | -2.86% | -43.33% |
04-19 | EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Exact Therapeutics Wins Regulatory Approvals for Patient Recruitment in Dose Expansion Study | MT |
Sales 2022 | 455K 41.22K 3.29M | Sales 2023 | 4.46K 404.32 32.27K | Capitalization | 385M 34.91M 2.79B |
---|---|---|---|---|---|
Net income 2022 | -40M -3.63M -290M | Net income 2023 | -48M -4.35M -347M | EV / Sales 2022 | 643 x |
Net cash position 2022 | 67.7M 6.14M 490M | Net cash position 2023 | 45.23M 4.1M 327M | EV / Sales 2023 | 76,207 x |
P/E ratio 2022 |
-8.96
x | P/E ratio 2023 |
-7.95
x | Employees | 12 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 32.3% |
1 week | -2.86% | ||
Current month | +13.33% | ||
1 month | +13.33% | ||
3 months | -43.33% | ||
6 months | -47.69% | ||
Current year | -43.33% |
Managers | Title | Age | Since |
---|---|---|---|
Svein Kvåle
FOU | Founder | - | 31/12/11 |
Per Walday
CEO | Chief Executive Officer | 64 | 27/03/22 |
John Edminson
DFI | Director of Finance/CFO | - | 30/09/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
William Castell
BRD | Director/Board Member | 76 | 21/06/18 |
Director/Board Member | 57 | - | |
Director/Board Member | 53 | 31/12/14 |
Date | Price | Change | Volume |
---|---|---|---|
30/04/24 | 6.8 | -.--% | 2,920 |
29/04/24 | 6.8 | -.--% | 0 |
26/04/24 | 6.8 | -.--% | 1,200 |
25/04/24 | 6.8 | -2.86% | 700 |
24/04/24 | 7 | -.--% | 0 |
Real-time Oslo Bors, April 30, 2024 at 03:45 pm
More quotes1st Jan change | Capi. | |
---|---|---|
-43.33% | 19.7M | |
+0.67% | 42.19B | |
+44.30% | 40.15B | |
-6.20% | 28.31B | |
+6.55% | 24.63B | |
-21.66% | 18.2B | |
+29.79% | 12.01B | |
-1.57% | 11.76B | |
+16.03% | 10.4B | |
-4.80% | 9.94B |
- Stock Market
- Equities
- EXTX Stock